News ALK-Abelló A/S

Stocks

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 21/07/2026 BST			5-day change	1st Jan Change
235.80 ^DKK	-0.76%		-1.91%	+3.15%

06-15	ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis	CI
06-15	UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment	MT

All News

Mentions Relevance

06-15	ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis	CI
06-15	UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment	MT
06-15	ALK Abelló A/S : EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis	PU
06-11	ALK Abelló A/S : Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap	PU
06-04	ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026	GL
06-01	Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff	GL
05-29	ALK to present at the Jefferies Global Healthcare Conference in New York	GL
05-28	Berenberg Starts ALK-Abelló at Buy on Growth Potential Amid Food Allergy Market Entry Plans	MT
05-04	ALK-Abelló A/S, Q1 2026 Earnings Call, May 04, 2026
05-04	ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	ALK Abelló A/S : Presentation	PU
05-04	ALK-Abelló Upgrades FY26 Revenue Outlook	MT
05-04	Alk-Abello Q1 Ebit up at DKK 570 million	RE
05-04	Three-month interim report (Q1) 2026 (unaudited)	GL
05-04	ALK upgrades its full-year outlook	GL
05-04	Alk-Abelló A/S Upgrades Earnings Guidance for the Full-Year 2026	CI
04-28	ALK Abelló A/S : Invitation to the presentation of ALK's first quarter 2026 results on Tuesday, 5 May 2026	PU
04-28	Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026	GL
04-20	ALK-Abelló Reports Positive Results from Mid-stage Trial of Peanut Allergy Treatment	MT
04-20	ALK-Abello announces successful outcome of phase 2 trial of peanut allergy tablet	RE
04-20	ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy	GL
04-20	ALK Announces Successful Outcome of Phase 2 Trial with Its Tablet for Treatment of Peanut Allergy Demonstrating Early Onset of Efficacy	CI
04-15	ALK-Abelló Receives Approval to Sell Needle-Free Anaphylaxis Treatment in Canada	MT
04-15	Alk-Abello says Neffy approved in Canada	RE
04-15	Neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada	GL